西妥昔单抗和/或纳武利尤单抗治疗复发性和/或转移性头颈部癌患者的药物性间质性肺病。
Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab.
机构信息
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
出版信息
Oral Oncol. 2021 Feb;113:105129. doi: 10.1016/j.oraloncology.2020.105129. Epub 2020 Dec 22.
BACKGROUND
Drug-induced interstitial lung disease (DI-IP) is one of the most serious adverse reactions associated with the use of anticancer drugs. DI-IP prevalence among molecular-targeting drugs and immune checkpoint inhibitors (ICIs) is relatively high in Japanese patients. To assess the risk of cetuximab and/or nivolumab-related IP is important.
PATIENTS AND METHODS
The medical records of 138 patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab-containing chemotherapy and/or nivolumab monotherapy were retrospectively reviewed.
RESULTS
The incidence of DI-IP with R/M HNSCC was 7.2%. DI-IP occurred more frequently in patients treated with cetuximab-containing chemotherapy following nivolumab monotherapy than in patients with other regimens. However, tumor suppression was detected in all patients treated with cetuximab-containing chemotherapy following nivolumab monotherapy, and two achieved a complete response.
CONCLUSIONS
Although patients treated with cetuximab-containing chemotherapy following nivolumab showed dramatic efficacy, careful monitoring should be recommended.
背景
药物性间质性肺病（DI-IP）是与抗癌药物使用相关的最严重的不良反应之一。在日本患者中，分子靶向药物和免疫检查点抑制剂（ICIs）相关的 DI-IP 发生率相对较高。评估西妥昔单抗和/或纳武利尤单抗相关的 IP 风险很重要。
患者和方法
回顾性分析了 138 例接受西妥昔单抗联合化疗和/或纳武利尤单抗单药治疗的复发性和/或转移性头颈部鳞状细胞癌患者的病历。
结果
R/M HNSCC 患者 DI-IP 的发生率为 7.2%。与其他方案相比，接受纳武利尤单抗单药治疗后再接受西妥昔单抗联合化疗的患者发生 DI-IP 的频率更高。然而，所有接受纳武利尤单抗单药治疗后再接受西妥昔单抗联合化疗的患者均检测到肿瘤抑制，其中 2 例达到完全缓解。
结论
尽管接受纳武利尤单抗单药治疗后再接受西妥昔单抗联合化疗的患者显示出显著的疗效，但应建议密切监测。
Zotero 插件